人类骨骼肌线粒体动力学与氧化能力和胰岛素敏感性的关系
该横断面研究比较了2型糖尿病、肥胖无糖尿病、瘦弱个体和耐力训练运动员四组人群骨骼肌中线粒体动力学与质量控制相关蛋白水平。结果显示,FIS1和OPA1蛋白含量在运动员中最高,在2型糖尿病和肥胖者中最低,且与氧化能力和胰岛素敏感性正相关。结论提示骨骼肌线粒体动力学与质量控制可能与维持肌肉胰岛素敏感性有关。
要点
- 运动员骨骼肌FIS1和OPA1蛋白含量最高,2型糖尿病和肥胖者最低。
- 2型糖尿病个体骨骼肌线粒体网络呈现碎片化。
- OPA1、FIS1和HSP60与氧化能力和胰岛素敏感性正相关。
核心结论
- 骨骼肌线粒体动力学和质量控制与人类氧化能力相关,可能参与维持肌肉胰岛素敏感性。
研究设计与样本
- 横断面设计,比较四组参与者:2型糖尿病(n=11)、肥胖无糖尿病(n=12)、瘦弱个体(n=10)和耐力训练运动员(n=12),分析过夜空腹肌肉活检中线粒体动力学和质量控制调节蛋白水平。
主要发现
- 2型糖尿病和肥胖参与者年龄分别为58.6±4.0和56.7±7.2岁,高于瘦弱个体(21.8±2.5岁)和运动员(25.1±4.3岁),p<0.001。
- 2型糖尿病和肥胖参与者BMI分别为32.4±3.7和31.0±3.7 kg/m2,高于瘦弱个体(22.1±1.8 kg/m2)和运动员(21.0±1.5 kg/m2),p<0.001。
- FIS1蛋白含量在运动员中最高(1.86±0.79 AU) vs 2型糖尿病最低(0.79±0.51 AU),p=0.002。
- OPA1蛋白含量在运动员中最高(1.55±0.64 AU) vs 肥胖者最低(0.76±0.52 AU),p=0.014。
- OPA1、FIS1和HSP60分别与氧化能力正相关(r=0.48, p=0.0001;r=0.55, p<0.001;r=0.61, p<0.0001),与胰岛素敏感性正相关(r=0.40, p=0.008;r=0.44, p=0.003;r=0.48, p=0.001)。
临床怎么用
- 骨骼肌线粒体动力学蛋白(FIS1、OPA1、HSP60)可能作为评估氧化能力和胰岛素敏感性的潜在生物标志物。
- 针对线粒体动力学和质量控制的干预或有助于改善骨骼肌胰岛素敏感性,但需进一步研究验证。
局限性
- 横断面设计无法确定因果关系。
- 2型糖尿病和肥胖参与者年龄显著大于瘦弱个体和运动员,可能混杂结果。
- 线粒体网络碎片化仅在部分参与者(2型糖尿病 vs 运动员,n=6)中通过共聚焦显微镜评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Mitochondria operate in networks, adapting to external stresses and changes in cellular metabolic demand and are subject to various quality control mechanisms. On the basis of these traits, we here hypothesise that the regulation of mitochondrial networks in skeletal muscle is hampered in humans with compromised oxidative capacity and insulin sensitivity. METHODS: In a cross-sectional design, we compared four groups of participants (selected from previous studies) ranging in aerobic capacity and insulin sensitivity, i.e. participants with type 2 diabetes (n = 11), obese participants without diabetes (n = 12), lean individuals (n = 10) and endurance-trained athletes (n = 12); basal, overnight fasted muscle biopsies were newly analysed for the current study and we compared the levels of essential mitochondrial dynamics and quality control regulatory proteins in skeletal muscle tissue. RESULTS: Type 2 diabetes patients and obese participants were older than lean participants and athletes (58.6 ± 4.0 and 56.7 ± 7.2 vs 21.8 ± 2.5 and 25.1 ± 4.3 years, p < 0.001, respectively) and displayed a higher BMI (32.4 ± 3.7 and 31.0 ± 3.7 vs 22.1 ± 1.8 and 21.0 ± 1.5 kg/m2, p < 0.001, respectively) than lean individuals and endurance-trained athletes. Fission protein 1 (FIS1) and optic atrophy protein 1 (OPA1) protein content was highest in muscle from athletes and lowest in participants with type 2 diabetes and obesity, respectively (FIS1: 1.86 ± 0.79 vs 0.79 ± 0.51 AU, p = 0.002; and OPA1: 1.55 ± 0.64 vs 0.76 ± 0.52 AU, p = 0.014), which coincided with mitochondrial network fragmentation in individuals with type 2 diabetes, as assessed by confocal microscopy in a subset of type 2 diabetes patients vs endurance-trained athletes (n = 6). Furthermore, lean individuals and athletes displayed a mitonuclear protein balance that was different from obese participants and those with type 2 diabetes. Mitonuclear protein balance also associated with heat shock protein 60 (HSP60) protein levels, which were higher in athletes when compared with participants with obesity (p = 0.048) and type 2 diabetes (p = 0.002), indicative for activation of the mitochondrial unfolded protein response. Finally, OPA1, FIS1 and HSP60 correlated positively with aerobic capacity (r = 0.48, p = 0.0001; r = 0.55, p < 0.001 and r = 0.61, p < 0.0001, respectively) and insulin sensitivity (r = 0.40, p = 0.008; r = 0.44, p = 0.003 and r = 0.48, p = 0.001, respectively). CONCLUSIONS/INTERPRETATION: Collectively, our data suggest that mitochondrial dynamics and quality control in skeletal muscle are linked to oxidative capacity in humans, which may play a role in the maintenance of muscle insulin sensitivity. CLINICAL TRIAL REGISTRY: numbers NCT00943059, NCT01298375 and NL1888 Graphical abstract.
引用
- Houzelle A, Jörgensen JA, Schaart G, et al. Human skeletal muscle mitochondrial dynamics in relation to oxidative capacity and insulin sensitivity. Diabetologia. 2020. PMID: 33258025. doi:10.1007/s00125-020-05335-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。